Maravai LifeSciences Holdings Inc
NASDAQ:MRVI

Watchlist Manager
Maravai LifeSciences Holdings Inc Logo
Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
Watchlist
Price: 5.33 USD 3.9%
Market Cap: 1.3B USD
Have any thoughts about
Maravai LifeSciences Holdings Inc?
Write Note

Maravai LifeSciences Holdings Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Maravai LifeSciences Holdings Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
Depreciation & Amortization
$40.3m
CAGR 3-Years
16%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Depreciation & Amortization
$3.2B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
8%
Danaher Corp
NYSE:DHR
Depreciation & Amortization
$2.3B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
10%
Mettler-Toledo International Inc
NYSE:MTD
Depreciation & Amortization
$123m
CAGR 3-Years
5%
CAGR 5-Years
7%
CAGR 10-Years
7%
Agilent Technologies Inc
NYSE:A
Depreciation & Amortization
$257m
CAGR 3-Years
-7%
CAGR 5-Years
2%
CAGR 10-Years
-4%
IQVIA Holdings Inc
NYSE:IQV
Depreciation & Amortization
$1.1B
CAGR 3-Years
-6%
CAGR 5-Years
-1%
CAGR 10-Years
25%
No Stocks Found

Maravai LifeSciences Holdings Inc
Glance View

Market Cap
1.3B USD
Industry
Life Sciences Tools & Services

Maravai LifeSciences Holdings Inc. operates in the niche yet burgeoning market of life sciences, where its business revolves around the creation and supply of essential products and services for biotechnology workflows. Founded in 2014 and headquartered in San Diego, California, Maravai specializes in providing key components for the development of diagnostics and therapeutics. A significant portion of its revenue is driven by its business unit, TriLink BioTechnologies, which is instrumental in the synthesis of nucleic acids, notably mRNA and modified nucleotides – critical for the development of mRNA vaccines like those used in combating COVID-19. This has positioned Maravai as a crucial player during the pandemic, spotlighting its capability to provide high-quality inputs that support leading-edge scientific innovations. The company’s financial engine is powered by its diversified product offerings across three main segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. Beyond just supplying raw materials, Maravai elevates its contributions by ensuring these components meet rigorous quality standards necessary for clinical applications. The robust demand for both biopharmaceutical innovation and bioprotection has allowed Maravai to capitalize on trends such as personalized medicine and gene therapy. By navigating these influential currents in the biotechnology space, Maravai LifeSciences not only gains from direct sales of its products but also cultivates long-standing partnerships across pharmaceutical and research organizations, underscoring its integral role in the ongoing evolution of life sciences.

MRVI Intrinsic Value
2.89 USD
Overvaluation 46%
Intrinsic Value
Price

See Also

What is Maravai LifeSciences Holdings Inc's Depreciation & Amortization?
Depreciation & Amortization
40.3m USD

Based on the financial report for Dec 31, 2023, Maravai LifeSciences Holdings Inc's Depreciation & Amortization amounts to 40.3m USD.

What is Maravai LifeSciences Holdings Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
13%

Over the last year, the Depreciation & Amortization growth was 26%. The average annual Depreciation & Amortization growth rates for Maravai LifeSciences Holdings Inc have been 16% over the past three years , 13% over the past five years .

Back to Top